Preventing the progression to type 2 diabetes can significantly reduce long-term health complications and even lessen the environmental impact of healthcare systems, according to research presented by Niels Lund, MSc, MBA, vice president of Changing Diabetes at Novo Nordisk.
Lund’s findings, detailed in a recent interview with Pharmacy Times, demonstrate a link between early intervention for prediabetes and improved patient outcomes, including reduced risks of cardiovascular, renal, and ophthalmic diseases. The research extends beyond individual health, revealing that proactive diabetes prevention strategies correlate with decreased greenhouse gas emissions across entire health systems.
The study, a collaborative analysis led by Lund, examined the “total patient carbon footprint,” factoring in elements such as medication, medical equipment, transportation, outpatient and inpatient care, and the consequences of complications associated with untreated type 2 diabetes. According to Lund, this footprint is influenced by a multitude of factors, and focusing on prediabetes treatment offers a substantial opportunity for improvement.
“We believe that the total patient carbon footprint…is influenced by many factors: medicine, equipment, transport, outpatient care, inpatient care, complications, and so on,” Lund told HCPLive. The research indicates that managing prediabetes effectively lowers this footprint compared to the comprehensive care required for established type 2 diabetes.
Pharmacists, according to Lund, are well-positioned to support these preventative efforts. The potential for improved quality of life and increased longevity through prediabetes prevention underscores the importance of their role in patient care. The findings were highlighted in a LinkedIn post by Pharmacy Times, emphasizing the dual benefits of diabetes prevention for both public health and environmental sustainability.
The collaborative analysis as well suggests that increased lifespans are achievable through early prediabetes treatment, a finding that adds another layer of significance to the research. Novo Nordisk’s involvement, through Lund’s leadership, positions the company at the forefront of this emerging understanding of the interconnectedness of healthcare and environmental impact.
